$ALHC
Alignment Healthcare, Inc. Stock $alhc

$alhc Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024021154 Filed on February 27, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$628.6M	$465.4M	$1.824B
YoY Change	43.14%	28.63%	27.16%
Cost Of Revenue	$573.2M	$417.8M	$1.623B
YoY Change	44.64%	28.15%	29.82%
Gross Profit	$55.38M	$47.63M	$201.0M
YoY Change	29.28%	33.0%	9.09%
Gross Profit Margin	8.81%	10.23%	11.02%
Selling, General & Admin	$90.51M	$83.74M	$307.4M
YoY Change	28.55%	0.61%	3.99%
% of Gross Profit	163.43%	175.83%	152.93%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$5.977M	$5.861M	$21.41M
YoY Change	21.46%	23.36%	23.97%
% of Gross Profit	10.79%	12.31%	10.65%
Operating Expenses	$669.7M	$89.54M	$1.951B
YoY Change	41.99%	1.85%	24.87%
Operating Profit	-$41.11M	-$41.91M	-$127.8M
YoY Change	26.52%	-19.56%	-0.64%
Interest Expense	$5.427M	-$5.484M	$21.23M
YoY Change	8.13%	14.42%	16.09%
% of Operating Profit
Other Income/Expense, Net	-$5.469M	$142.0K	-$20.38M
YoY Change	12.05%	86.84%	-1.37%
Pretax Income	-$46.58M	-$47.26M	-$148.2M
YoY Change	24.63%	-16.84%	-0.74%
Income Tax	$0.00	-$24.00K	-$22.00K
% Of Pretax Income
Net Earnings	-$46.52M	-$47.21M	-$148.0M
YoY Change	24.77%	-17.04%	-1.02%
Net Earnings / Revenue	-7.4%	-10.14%	-8.12%
Basic Earnings Per Share	-$0.25		-$0.79
Diluted Earnings Per Share	-$0.25	-$0.25	-$0.79
COMMON SHARES
Basic Shares Outstanding	189.0M	189.1M	188.4M
Diluted Shares Outstanding	189.0M shares		188.4M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$301.7M	$318.8M	$318.8M
YoY Change	-38.14%	-22.15%	-22.15%
Cash & Equivalents	$238.9M	$202.9M
Short-Term Investments	$62.81M	$115.9M	$115.9M
Other Short-Term Assets	$53.86M	$44.97M	$44.97M
YoY Change	-6.97%	6.8%	6.8%
Inventory
Prepaid Expenses
Receivables	$165.1M	$119.7M	$0.00
Other Receivables	$165.1M	$119.7M	$119.7M
Total Short-Term Assets	$520.6M	$483.5M	$483.5M
YoY Change	-22.4%	-11.2%	-11.2%
LONG-TERM ASSETS
Property, Plant & Equipment	$57.21M	$51.90M	$61.86M
YoY Change	44.42%	39.64%	43.88%
Goodwill	$34.83M	$34.83M
YoY Change	0.05%	0.05%
Intangibles	$5.224M	$5.252M
YoY Change		-4.13%
Long-Term Investments
YoY Change
Other Assets	$6.781M	$6.405M	$6.405M
YoY Change	13.85%	6.13%	6.13%
Total Long-Term Assets	$112.6M	$108.3M	$108.3M
YoY Change	23.95%	21.3%	21.3%
TOTAL ASSETS
Total Short-Term Assets	$520.6M	$483.5M	$483.5M
Total Long-Term Assets	$112.6M	$108.3M	$108.3M
Total Assets	$633.2M	$591.9M	$591.9M
YoY Change	-16.87%	-6.62%	-6.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$299.1M	$228.9M	$227.2M
YoY Change	43.45%	13.08%	14.62%
Accrued Expenses	$31.61M	$34.11M	$35.71M
YoY Change	28.64%	23.87%	13.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$120.0K
YoY Change			-21.05%
Total Short-Term Liabilities	$330.7M	$263.0M	$263.0M
YoY Change	-11.61%	14.38%	14.38%
LONG-TERM LIABILITIES
Long-Term Debt	$162.0M	$161.8M	$161.8M
YoY Change	0.56%	0.57%	0.49%
Other Long-Term Liabilities	$8.441M	$8.974M	$8.974M
YoY Change	237.24%	142.67%	150.81%
Total Long-Term Liabilities	$162.0M	$161.8M	$170.8M
YoY Change	0.56%	0.57%	3.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$330.7M	$263.0M	$263.0M
Total Long-Term Liabilities	$162.0M	$161.8M	$170.8M
Total Liabilities	$501.2M	$433.8M	$434.9M
YoY Change	-6.8%	9.95%	9.9%
SHAREHOLDERS EQUITY
Retained Earnings	-$926.8M	-$880.3M
YoY Change	20.44%	20.21%
Common Stock	$191.0K	$189.0K
YoY Change	1.6%	1.07%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$130.9M	$156.9M	$156.9M
YoY Change
Total Liabilities & Shareholders Equity	$633.2M	$591.9M	$591.9M
YoY Change	-16.87%	-6.62%	-6.62%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$46.52M	-$47.21M	-$148.0M
YoY Change	24.77%	-17.04%	-1.02%
Depreciation, Depletion And Amortization	$5.977M	$5.861M	$21.41M
YoY Change	21.46%	23.36%	23.97%
Cash From Operating Activities	-$6.238M	-$187.5M	-$59.19M
YoY Change	-107.33%	25.59%	30.29%
INVESTING ACTIVITIES
Capital Expenditures	$11.12M	$10.60M	$36.00M
YoY Change	52.66%	64.12%	51.4%
Acquisitions			$0.00
YoY Change
Other Investing Activities	$53.83M	$9.579M	-$111.3M
YoY Change	-152.19%	-680.55%	2404.34%
Cash From Investing Activities	$42.71M	-$1.018M	-$147.3M
YoY Change	-138.67%	-87.44%	421.89%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change
Debt Paid & Issued, Net			$0.00
YoY Change			-100.0%
Cash From Financing Activities	-$335.0K	45.00K	105.0K
YoY Change	-1216.67%	-108.54%	-99.37%
NET CHANGE
Cash From Operating Activities	-$6.238M	-187.5M	-59.19M
Cash From Investing Activities	$42.71M	-1.018M	-147.3M
Cash From Financing Activities	-$335.0K	45.00K	105.0K
Net Change In Cash	$36.13M	-188.4M	-206.3M
YoY Change	-242.88%	19.34%	261.69%
FREE CASH FLOW
Cash From Operating Activities	-$6.238M	-$187.5M	-$59.19M
Capital Expenditures	$11.12M	$10.60M	$36.00M
Free Cash Flow	-$17.36M	-$198.1M	-$95.18M
YoY Change	-122.31%	27.19%	37.54%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001832466
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#FinancialServiceMember
CY2022	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#FinancialServiceMember
CY2021	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2023#FinancialServiceMember
CY2023	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
CY2022	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2022Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2023Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2022Q4	us-gaap	Finance Lease Liability Current Statement Of Financial Position Extensible List FinanceLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#LiabilitiesCurrent
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#Liabilities
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent Statement Of Financial Position Extensible List FinanceLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#Liabilities
CY2023Q4	us-gaap	Finance Lease Liability Statement Of Financial Position Extensible List FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#Liabilities
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-40295
CY2023	dei	Entity Registrant Name EntityRegistrantName	ALIGNMENT HEALTHCARE, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-5596242
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	1100 W. Town and Country Road
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 1600
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Orange
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92868
CY2023	dei	City Area Code CityAreaCode	844
CY2023	dei	Local Phone Number LocalPhoneNumber	310-2247
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	ALHC
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	32288000
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	675468842
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	188977667
CY2023	dei	Auditor Firm AuditorFirmId	34
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	Los Angeles, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	202904000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	409549000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	119749000
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	92890000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	44970000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	42107000
CY2023Q4	us-gaap	Short Term Investments ShortTermInvestments	115914000
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	0
CY2023Q4	us-gaap	Assets Current AssetsCurrent	483537000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	544546000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	51901000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37169000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9959000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5825000
CY2023Q4	us-gaap	Goodwill Goodwill	34826000
CY2022Q4	us-gaap	Goodwill Goodwill	34810000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5252000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	5478000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6405000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	6035000
CY2023Q4	us-gaap	Assets Assets	591880000
CY2022Q4	us-gaap	Assets Assets	633863000
CY2023Q4	alhc	Medical Expenses Payable Current MedicalExpensesPayableCurrent	205399000
CY2022Q4	alhc	Medical Expenses Payable Current MedicalExpensesPayableCurrent	170135000
CY2023Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	23511000
CY2023Q4	alhc	Accrued Compensation AccruedCompensation	34112000
CY2022Q4	alhc	Accrued Compensation AccruedCompensation	27538000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	263022000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	229961000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	161813000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	160902000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8974000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3698000
CY2023Q4	us-gaap	Liabilities Liabilities	433809000
CY2022Q4	us-gaap	Liabilities Liabilities	394561000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	100000000
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	188951643
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	188951643
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	187280015
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	187280015
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	189000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	187000
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1037015000
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	970180000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-880258000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-732241000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	156946000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	238126000
CY2023Q4	us-gaap	Minority Interest MinorityInterest	1125000
CY2022Q4	us-gaap	Minority Interest MinorityInterest	1176000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	158071000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	239302000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	591880000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	633863000
CY2023	us-gaap	Premiums Earned Net PremiumsEarnedNet	1800933000
CY2022	us-gaap	Premiums Earned Net PremiumsEarnedNet	1431550000
CY2021	us-gaap	Premiums Earned Net PremiumsEarnedNet	1167085000
CY2023	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	22697000
CY2023	alhc	Medical Expenses MedicalExpenses	1622600000
CY2022	alhc	Medical Expenses MedicalExpenses	1249879000
CY2021	alhc	Medical Expenses MedicalExpenses	1039041000
CY2022	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	2609000
CY2021	us-gaap	Revenue Not From Contract With Customer RevenueNotFromContractWithCustomer	688000
CY2023	us-gaap	Revenues Revenues	1823630000
CY2022	us-gaap	Revenues Revenues	1434159000
CY2021	us-gaap	Revenues Revenues	1167773000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	307433000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	295646000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	290991000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	21414000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	17273000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	15813000
CY2023	us-gaap	Operating Expenses OperatingExpenses	1951447000
CY2022	us-gaap	Operating Expenses OperatingExpenses	1562798000
CY2021	us-gaap	Operating Expenses OperatingExpenses	1345845000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-127817000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-128639000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-178072000
CY2023	us-gaap	Interest Expense InterestExpense	21231000
CY2022	us-gaap	Interest Expense InterestExpense	18289000
CY2021	us-gaap	Interest Expense InterestExpense	17443000
CY2023	alhc	Other Non Operating Expense Income OtherNonOperatingExpenseIncome	-853000
CY2022	alhc	Other Non Operating Expense Income OtherNonOperatingExpenseIncome	176000
CY2021	alhc	Other Non Operating Expense Income OtherNonOperatingExpenseIncome	-229000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2196000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20378000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-20661000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-17214000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-148195000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-149300000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-195286000
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-22000
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	339000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023	us-gaap	Profit Loss ProfitLoss	-148173000
CY2022	us-gaap	Profit Loss ProfitLoss	-149639000
CY2021	us-gaap	Profit Loss ProfitLoss	-195286000
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-156000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-92000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-148017000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-149547000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-195286000
CY2023	alhc	Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasic	186214784
CY2023	alhc	Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Diluted WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockDiluted	186214784
CY2022	alhc	Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasic	181212757
CY2022	alhc	Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Diluted WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockDiluted	181212757
CY2021	alhc	Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasic	171956849
CY2021	alhc	Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Diluted WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockDiluted	171956849
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.14
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.14
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	30611000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-195286000
CY2021	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	15000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	361589000
CY2021	alhc	Stock Issued During Period Value To The Third Party Business Providers StockIssuedDuringPeriodValueToTheThirdPartyBusinessProviders	6480000
CY2021	us-gaap	Stock Issued During Period Value Employee Benefit Plan StockIssuedDuringPeriodValueEmployeeBenefitPlan	11510000
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	1000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	92611000
CY2021	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1474000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	306055000
CY2022	us-gaap	Profit Loss ProfitLoss	-149639000
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	0
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	81718000
CY2022	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	1168000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	239302000
CY2023	us-gaap	Profit Loss ProfitLoss	-148173000
CY2023	alhc	Issuance Of Common Stock Upon Vesting Of Restricted Stock Units Values IssuanceOfCommonStockUponVestingOfRestrictedStockUnitsValues	2000
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation Forfeited StockIssuedDuringPeriodValueShareBasedCompensationForfeited	0
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	66835000
CY2023	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	105000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	158071000
CY2023	us-gaap	Profit Loss ProfitLoss	-148173000
CY2022	us-gaap	Profit Loss ProfitLoss	-149639000
CY2021	us-gaap	Profit Loss ProfitLoss	-195286000
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	91000
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	150000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	111000
CY2023	alhc	Gain Loss On Right Of Use Assets GainLossOnRightOfUseAssets	289000
CY2022	alhc	Gain Loss On Right Of Use Assets GainLossOnRightOfUseAssets	-510000
CY2021	alhc	Gain Loss On Right Of Use Assets GainLossOnRightOfUseAssets	0
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	21668000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	17486000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	16033000
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	-3663000
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	1850000
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	2254000
CY2023	us-gaap	Paid In Kind Interest PaidInKindInterest	0
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	2943000
CY2021	us-gaap	Paid In Kind Interest PaidInKindInterest	4197000
CY2023	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2022	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-101000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0
CY2023	alhc	Share Based Compensation And Common Stock Payments ShareBasedCompensationAndCommonStockPayments	66835000
CY2022	alhc	Share Based Compensation And Common Stock Payments ShareBasedCompensationAndCommonStockPayments	81718000
CY2021	alhc	Share Based Compensation And Common Stock Payments ShareBasedCompensationAndCommonStockPayments	110600000
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	2318000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	2811000
CY2022	alhc	Increase Decrease In Medical Expenses Payable IncreaseDecreaseInMedicalExpensesPayable	44250000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	2731000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-0
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-2196000
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	26950000
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	34377000
CY2021	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	17608000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2863000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	14356000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	10340000
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	142000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	86000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-644000
CY2023	alhc	Increase Decrease In Medical Expenses Payable IncreaseDecreaseInMedicalExpensesPayable	35264000
CY2021	alhc	Increase Decrease In Medical Expenses Payable IncreaseDecreaseInMedicalExpensesPayable	12512000
CY2023	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-6347000
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	13743000
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	437000
CY2023	alhc	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	6574000
CY2022	alhc	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	3609000
CY2021	alhc	Increase Decrease In Accrued Compensation IncreaseDecreaseInAccruedCompensation	-1244000
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3510000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4214000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-3817000
CY2023	alhc	Increase Decrease In Debt Instrument Payment In Kind Interest On Principal Balance IncreaseDecreaseInDebtInstrumentPaymentInKindInterestOnPrincipalBalance	0
CY2022	alhc	Increase Decrease In Debt Instrument Payment In Kind Interest On Principal Balance IncreaseDecreaseInDebtInstrumentPaymentInKindInterestOnPrincipalBalance	-14122000
CY2021	alhc	Increase Decrease In Debt Instrument Payment In Kind Interest On Principal Balance IncreaseDecreaseInDebtInstrumentPaymentInKindInterestOnPrincipalBalance	0
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-59187000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-45427000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-78776000
CY2023	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	0
CY2022	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	4043000
CY2021	us-gaap	Payments To Acquire Assets Investing Activities PaymentsToAcquireAssetsInvestingActivities	0
CY2023	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2022	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2021	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	1405000
CY2023	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	379058000
CY2022	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2825000
CY2021	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	2475000
CY2023	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	267790000
CY2022	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	2425000
CY2021	us-gaap	Proceeds From Sale Of Longterm Investments ProceedsFromSaleOfLongtermInvestments	1425000
CY2023	alhc	Proceeds From Acquisition Of Property And Equipment ProceedsFromAcquisitionOfPropertyAndEquipment	-35995000
CY2022	alhc	Proceeds From Acquisition Of Property And Equipment ProceedsFromAcquisitionOfPropertyAndEquipment	-23774000
CY2021	alhc	Proceeds From Acquisition Of Property And Equipment ProceedsFromAcquisitionOfPropertyAndEquipment	-18360000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-147263000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-28217000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-20815000
CY2023	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	0
CY2022	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	100000
CY2021	us-gaap	Payments To Minority Shareholders PaymentsToMinorityShareholders	0
CY2023	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	105000
CY2022	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	68000
CY2021	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	15000
CY2023	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	0
CY2022	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	0
CY2021	us-gaap	Payments For Repurchase Of Equity PaymentsForRepurchaseOfEquity	1474000
CY2023	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0
CY2022	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	165000000
CY2021	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	5196000
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	143179000
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	390600000
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
CY2022	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0
CY2021	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	29011000
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	105000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	16593000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	360130000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-206345000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-57051000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	260539000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	411299000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	468350000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	207811000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	204954000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	411299000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	468350000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	19165000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	22447000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	10992000
CY2023	alhc	Acquisition Of Property In Accounts Payable AcquisitionOfPropertyInAccountsPayable	59000
CY2022	alhc	Acquisition Of Property In Accounts Payable AcquisitionOfPropertyInAccountsPayable	47000
CY2021	alhc	Acquisition Of Property In Accounts Payable AcquisitionOfPropertyInAccountsPayable	347000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	505000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	0
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	202904000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	409549000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	466600000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	2050000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1750000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	1750000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	204954000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	411299000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	468350000
CY2021Q4	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	9200000
CY2021Q4	us-gaap	Sale Of Stock Consideration Received On Transaction SaleOfStockConsiderationReceivedOnTransaction	0
CY2021Q4	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1045000
CY2023	alhc	Number Of Consolidated Variable Interest Entities NumberOfConsolidatedVariableInterestEntities	3
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">preparation of the consolidated financial statements requires management to make estimates and judgments that affect the amounts reported in the consolidated financial statements. Our significant estimates include, but are not limited to, the determination of medical expenses payable; the impact of risk adjustment provisions related to our Medicare contracts; collectability of receivables; valuation of related impairment recognition of</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">long-lived </span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">assets, including goodwill and intangible assets; equity-based compensation expense; and contingent liabilities. Estimates and judgments are based upon historical information and on various other assumptions that are believed to be reasonable under the circumstances. Actual results could differ materially from those estimates and the impact of any change in estimates is included in earnings in the period in which the estimate is adjusted.</span></p>
CY2023	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1800933000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1431550000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	1167085000
CY2023	alhc	Interest Income InterestIncome	19586000
CY2022	alhc	Interest Income InterestIncome	1010000
CY2021	alhc	Interest Income InterestIncome	8000
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	22232000
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	50000
CY2023	alhc	Schedule Of Property And Equipment Estimated Useful Lives Table Textblock ScheduleOfPropertyAndEquipmentEstimatedUsefulLivesTableTextblock	<p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Depreciation expense is computed using the straight-line method generally based on the following estimated useful lives:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:72.206%;"></td> <td style="width:1.64%;"></td> <td style="width:26.155%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Estimated Service Lives (years)</span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Computer and equipment</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Office equipment and furniture</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7</span></span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Software</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3</span></span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">-</span><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">5</span></span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Leasehold improvements</span></p></td> <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">15 (or lease term, if shorter)</span></span></p></td> </tr> </table>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentrations of Credit Risk</span></p><p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash deposits and current and restricted investments with financial institutions. Accounts at each financial institution are insured by the Federal Deposit Insurance Corporation (“FDIC”) up to certain limits. At December 31, 2023 and December 31, 2022, there</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> was $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">316,977</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> and $</span><span style="font-size:9pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;min-width:fit-content;">408,047</span><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">, respectively, in excess of FDIC-insured limits.</span></p>
CY2023	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	316977000
CY2022	us-gaap	Federal Deposit Insurance Corporation Premium Expense FederalDepositInsuranceCorporationPremiumExpense	408047000
CY2023	us-gaap	Advertising Expense AdvertisingExpense	6956000
CY2022	us-gaap	Advertising Expense AdvertisingExpense	7958000
CY2021	us-gaap	Advertising Expense AdvertisingExpense	3581000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1 ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1	P4Y
CY2022	alhc	Equity Net Loss Attributable To Non Controlling Interest EquityNetLossAttributableToNonControllingInterest	0
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-156000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-92000
CY2023	us-gaap	Profit Loss ProfitLoss	-148173000
CY2022	us-gaap	Profit Loss ProfitLoss	-149639000
CY2021	us-gaap	Profit Loss ProfitLoss	-195286000
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-156000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-92000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-148017000
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-149547000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-195286000
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	188420487
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	188420487
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	187227877
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	187227877
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	181917964
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	181917964
CY2023	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	2205703
CY2022	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	6015120
CY2021	us-gaap	Weighted Average Number Of Shares Restricted Stock WeightedAverageNumberOfSharesRestrictedStock	9961115
CY2023	alhc	Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Diluted WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockDiluted	186214784
CY2023	alhc	Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasic	186214784
CY2022	alhc	Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Diluted WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockDiluted	181212757
CY2022	alhc	Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasic	181212757
CY2021	alhc	Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Basic WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockBasic	171956849
CY2021	alhc	Weighted Average Number Of Shares Outstanding Net Of Restricted Shares Of Common Stock Diluted WeightedAverageNumberOfSharesOutstandingNetOfRestrictedSharesOfCommonStockDiluted	171956849
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.79
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.79
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.14
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.14
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	26910709
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19332429
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	12600803
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	119092000
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	2860000
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2021	us-gaap	Asset Impairment Charges AssetImpairmentCharges	0
CY2023Q4	us-gaap	Government Contract Receivable GovernmentContractReceivable	35529000
CY2022Q4	us-gaap	Government Contract Receivable GovernmentContractReceivable	33200000
CY2023Q4	alhc	Pharmacy Rebates PharmacyRebates	-75894000
CY2022Q4	alhc	Pharmacy Rebates PharmacyRebates	-54605000
CY2023Q4	us-gaap	Other Receivables OtherReceivables	8326000
CY2022Q4	us-gaap	Other Receivables OtherReceivables	5085000
CY2023Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	119749000
CY2022Q4	us-gaap	Accounts Receivable Gross AccountsReceivableGross	92890000
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2023Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	119749000
CY2022Q4	us-gaap	Accounts Receivable Net AccountsReceivableNet	92890000
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	91000
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	150000
CY2021	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	111000
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	175586000
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	142333000
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	123685000
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	105164000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	51901000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	37169000
CY2023	us-gaap	Depreciation Depreciation	21442000
CY2022	us-gaap	Depreciation Depreciation	17100000
CY2021	us-gaap	Depreciation Depreciation	15671000
CY2023Q4	us-gaap	Goodwill Gross GoodwillGross	34826000
CY2023Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0
CY2023Q4	us-gaap	Goodwill Goodwill	34826000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	43543000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3465000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	40078000
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	34810000
CY2022Q4	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	0
CY2022Q4	us-gaap	Goodwill Goodwill	34810000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	43527000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3239000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	40288000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	226000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	386000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	362000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	82000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	60000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	60000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	60000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	23000
CY2023Q4	alhc	Estimated Amortization Expense Related To Intangible Assets EstimatedAmortizationExpenseRelatedToIntangibleAssets	285000
CY2023	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2022	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2021	us-gaap	Goodwill And Intangible Asset Impairment GoodwillAndIntangibleAssetImpairment	0
CY2023	us-gaap	Schedule Of Liability For Unpaid Claims And Claims Adjustment Expense ScheduleOfLiabilityForUnpaidClaimsAndClaimsAdjustmentExpense	<p style="font-size:10pt;margin-top:9pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">The following table is a detail of medical expenses payable as of December 31, 2023 and 2022:</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"> <tr style="visibility:collapse;"> <td style="width:66.673%;"></td> <td style="width:1.74%;"></td> <td style="width:1%;"></td> <td style="width:12.923%;"></td> <td style="width:1%;"></td> <td style="width:1.74%;"></td> <td style="width:1%;"></td> <td style="width:12.923%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;"> <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2023</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31,<br/>2022</span></p></td> <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Claims incurred but not paid</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,664</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">88,813</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Capitation and risk-sharing payable</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,894</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">50,818</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">58,841</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30,504</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;background-color:#ffffff;word-break:break-word;"> <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Medical expenses payable</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">205,399</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;"> </span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;min-width:fit-content;">$</span></p></td> <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">170,135</span></p></td> <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="min-width:fit-content;"> </span></p></td> </tr> </table>
CY2023Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	95664000
CY2022Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	88813000
CY2023Q4	alhc	Liability For Claims And Claims Capitation Payable And Risk Sharing Payable LiabilityForClaimsAndClaimsCapitationPayableAndRiskSharingPayable	50894000
CY2022Q4	alhc	Liability For Claims And Claims Capitation Payable And Risk Sharing Payable LiabilityForClaimsAndClaimsCapitationPayableAndRiskSharingPayable	50818000
CY2023Q4	alhc	Liability For Claims And Claims Other Medical Expenses Payable LiabilityForClaimsAndClaimsOtherMedicalExpensesPayable	58841000
CY2022Q4	alhc	Liability For Claims And Claims Other Medical Expenses Payable LiabilityForClaimsAndClaimsOtherMedicalExpensesPayable	30504000
CY2023Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	205399000
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	170135000
CY2022Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	88813000
CY2021Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	77073000
CY2020Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	82391000
CY2023	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	492315000
CY2022	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	400939000
CY2021	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Current Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersCurrentYearClaimsAndClaimsAdjustmentExpense	327224000
CY2023	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-14555000
CY2022	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-15402000
CY2021	us-gaap	Supplemental Information For Property Casualty Insurance Underwriters Prior Year Claims And Claims Adjustment Expense SupplementalInformationForPropertyCasualtyInsuranceUnderwritersPriorYearClaimsAndClaimsAdjustmentExpense	-8064000
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	477760000
CY2022	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	385537000
CY2021	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred Claims1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredClaims1	319160000
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	400465000
CY2022	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	315187000
CY2021	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Current Year1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidCurrentYear1	251629000
CY2023	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	70444000
CY2022	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	58610000
CY2021	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Claims Paid Prior Years1 LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseClaimsPaidPriorYears1	72849000
CY2023	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	470909000
CY2022	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	373797000
CY2021	us-gaap	Payments For Losses And Loss Adjustment Expense PaymentsForLossesAndLossAdjustmentExpense	324478000
CY2023Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	95664000
CY2022Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	88813000
CY2021Q4	us-gaap	Liability For Unpaid Claims And Claims Adjustment Expense Incurred But Not Reported Ibnr Claims Amount LiabilityForUnpaidClaimsAndClaimsAdjustmentExpenseIncurredButNotReportedIBNRClaimsAmount	77073000
CY2023Q4	alhc	Liability For Claims And Claims Capitation Payable Risk Sharing Payable And Other LiabilityForClaimsAndClaimsCapitationPayableRiskSharingPayableAndOther	109735000
CY2022Q4	alhc	Liability For Claims And Claims Capitation Payable Risk Sharing Payable And Other LiabilityForClaimsAndClaimsCapitationPayableRiskSharingPayableAndOther	81322000
CY2021Q4	alhc	Liability For Claims And Claims Capitation Payable Risk Sharing Payable And Other LiabilityForClaimsAndClaimsCapitationPayableRiskSharingPayableAndOther	48813000
CY2023Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	205399000
CY2022Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	170135000
CY2021Q4	us-gaap	Liability For Claims And Claims Adjustment Expense LiabilityForClaimsAndClaimsAdjustmentExpense	125886000
CY2023	alhc	Claims Reserve Estimates Excluding Provision From Prior Year Claims And Claims Adjustment Expense ClaimsReserveEstimatesExcludingProvisionFromPriorYearClaimsAndClaimsAdjustmentExpense	10996000
CY2022	alhc	Claims Reserve Estimates Excluding Provision From Prior Year Claims And Claims Adjustment Expense ClaimsReserveEstimatesExcludingProvisionFromPriorYearClaimsAndClaimsAdjustmentExpense	11179000
CY2021	alhc	Claims Reserve Estimates Excluding Provision From Prior Year Claims And Claims Adjustment Expense ClaimsReserveEstimatesExcludingProvisionFromPriorYearClaimsAndClaimsAdjustmentExpense	4166000
CY2023Q4	us-gaap	Shortduration Insurance Contracts Incurred Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsIncurredClaimsAndAllocatedClaimAdjustmentExpenseNet	1191438000
CY2023Q4	us-gaap	Shortduration Insurance Contracts Cumulative Paid Claims And Allocated Claim Adjustment Expense Net ShortdurationInsuranceContractsCumulativePaidClaimsAndAllocatedClaimAdjustmentExpenseNet	1095946000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	165000000
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	165000000
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	3187000
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet	4098000
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	161813000
CY2022Q4	us-gaap	Long Term Debt LongTermDebt	160902000
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	161813000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	160902000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	1650000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	1650000
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	161700000
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	165000000
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-31121000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-31353000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-41010000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	29426000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.199
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	82922000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.555
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	42597000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.218
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-5173000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.034
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-58286000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.39
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-10412000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.053
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	169000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.001
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	334000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.002
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	293000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	-0.001
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	0
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	621000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.003
CY2023	alhc	Effective Income Tax Rate Reconciliation Cumulative Deferred Adjustment And Others EffectiveIncomeTaxRateReconciliationCumulativeDeferredAdjustmentAndOthers	-947000
CY2023	alhc	Effective Income Tax Rate Reconciliation Cumulative Deferred Adjustment And Other Percentage EffectiveIncomeTaxRateReconciliationCumulativeDeferredAdjustmentAndOtherPercentage	0.006
CY2022	alhc	Effective Income Tax Rate Reconciliation Cumulative Deferred Adjustment And Others EffectiveIncomeTaxRateReconciliationCumulativeDeferredAdjustmentAndOthers	-1510000
CY2022	alhc	Effective Income Tax Rate Reconciliation Cumulative Deferred Adjustment And Other Percentage EffectiveIncomeTaxRateReconciliationCumulativeDeferredAdjustmentAndOtherPercentage	0.011
CY2021	alhc	Effective Income Tax Rate Reconciliation Cumulative Deferred Adjustment And Others EffectiveIncomeTaxRateReconciliationCumulativeDeferredAdjustmentAndOthers	-394000
CY2021	alhc	Effective Income Tax Rate Reconciliation Cumulative Deferred Adjustment And Other Percentage EffectiveIncomeTaxRateReconciliationCumulativeDeferredAdjustmentAndOtherPercentage	0.002
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	908000
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.006
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	231000
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2021	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-11000
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	6716000
CY2023	alhc	Income Tax Reconciliation Nondeductible Expense Percent IncomeTaxReconciliationNondeductibleExpensePercent	-0.045
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	8001000
CY2022	alhc	Income Tax Reconciliation Nondeductible Expense Percent IncomeTaxReconciliationNondeductibleExpensePercent	-0.054
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	8316000
CY2021	alhc	Income Tax Reconciliation Nondeductible Expense Percent IncomeTaxReconciliationNondeductibleExpensePercent	-0.043
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-22000
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.001
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	339000
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	-0.002
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0
CY2023Q4	alhc	Deferred Tax Assets Operating Loss Carryforwards Federal State And Local DeferredTaxAssetsOperatingLossCarryforwardsFederalStateAndLocal	151052000
CY2022Q4	alhc	Deferred Tax Assets Operating Loss Carryforwards Federal State And Local DeferredTaxAssetsOperatingLossCarryforwardsFederalStateAndLocal	141278000
CY2023Q4	alhc	Deferred Tax Assets Employee Benefits DeferredTaxAssetsEmployeeBenefits	49650000
CY2022Q4	alhc	Deferred Tax Assets Employee Benefits DeferredTaxAssetsEmployeeBenefits	80014000
CY2023Q4	alhc	Deferred Tax Assets Interest Deduction Limitation DeferredTaxAssetsInterestDeductionLimitation	12019000
CY2022Q4	alhc	Deferred Tax Assets Interest Deduction Limitation DeferredTaxAssetsInterestDeductionLimitation	25341000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3560000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	261000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	216281000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	246894000
CY2023Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	476000
CY2022Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	2381000
CY2023Q4	alhc	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	1052000
CY2022Q4	alhc	Deferred Tax Liabilities Depreciation DeferredTaxLiabilitiesDepreciation	1246000
CY2023Q4	alhc	Deferred Tax Liabilities Lease Liabilities DeferredTaxLiabilitiesLeaseLiabilities	2755000
CY2022Q4	alhc	Deferred Tax Liabilities Lease Liabilities DeferredTaxLiabilitiesLeaseLiabilities	1456000
CY2023Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	56000
CY2022Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	0
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	4339000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5083000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	211942000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	241811000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	211942000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	241811000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2023Q4	alhc	Operating Loss Carryforward Indefinite Life OperatingLossCarryforwardIndefiniteLife	312446000
CY2023	alhc	Operating Loss Carryforwards Expiration Year OperatingLossCarryforwardsExpirationYear	2033
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	11263389
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	18.02
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	324868
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	18.15
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10938521
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	18.02
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y2M1D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1370211
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.1
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1705239
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	17.8
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10603493
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.9
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y3M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	3519000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1467614
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	16.6
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9135879
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	16.95
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y3M14D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	79000
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	4219102
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	17.43
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y2M26D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	20000
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0
CY2023	alhc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue	0
CY2022	alhc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue	5685000
CY2021	alhc	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodFairValue	85043000
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares	113243
CY2023	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	79355
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	66835000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	81718000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	121999000
CY2023	alhc	Description Of Tangible Net Equity Requirement DescriptionOfTangibleNetEquityRequirement	The required amount is the larger of: (1) $1,000; (2) 2% of the first $150,000 of annualized premium revenue, plus 1% of annualized premium revenue in excess of $150,000; or (3) 8% of the first $150,000 of annualized health care expenditures, except for those paid on a capitated or managed hospital payment basis, plus 4% of the annualized health care expenditures in excess of $150,000, except those paid on a capitated or managed hospital payment basis, plus 4% of annualized hospital expenditures paid on a managed hospital payment basis. We were in compliance with the TNE requirement for all periods presented.
CY2023Q4	alhc	Tangible Net Equity Required Amount TangibleNetEquityRequiredAmount	1000000
CY2023	alhc	Annualized Premium Revenue Percentage AnnualizedPremiumRevenuePercentage	0.02
CY2023Q4	us-gaap	Tangible Capital Required For Capital Adequacy TangibleCapitalRequiredForCapitalAdequacy	150000000
CY2023	alhc	Annualized Premium Revenue Excess Amount Percentage AnnualizedPremiumRevenueExcessAmountPercentage	0.01
CY2023	alhc	Annualized Health Care Expenditures Percentage AnnualizedHealthCareExpendituresPercentage	0.08
CY2023	alhc	Annualized Health Care Expenditures Excess Amount Percentage AnnualizedHealthCareExpendituresExcessAmountPercentage	0.04
CY2023	alhc	Annualized Hospital Expenditure Paid Percentage AnnualizedHospitalExpenditurePaidPercentage	0.04
CY2023Q4	alhc	Banking Regulation Tangible Capital BankingRegulationTangibleCapital	111967000
CY2022Q4	alhc	Banking Regulation Tangible Capital BankingRegulationTangibleCapital	78541000
CY2023Q4	us-gaap	Excess Tangible Capital ExcessTangibleCapital	48326000
CY2022Q4	us-gaap	Excess Tangible Capital ExcessTangibleCapital	44239000
CY2023Q4	us-gaap	Statutory Accounting Practices Statutory Amount Available For Dividend Payments Without Regulatory Approval StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval	24349000
CY2022Q4	us-gaap	Statutory Accounting Practices Statutory Amount Available For Dividend Payments Without Regulatory Approval StatutoryAccountingPracticesStatutoryAmountAvailableForDividendPaymentsWithoutRegulatoryApproval	11086000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9959000
CY2023Q4	alhc	Operating Lease Liability Current Accounts Payable And Accrued Expenses OperatingLeaseLiabilityCurrentAccountsPayableAndAccruedExpenses	1717000
CY2023Q4	alhc	Operating Lease Liability Non Current Long Term Lease Liabilities OperatingLeaseLiabilityNonCurrentLongTermLeaseLiabilities	8974000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5825000
CY2022Q4	alhc	Operating Lease Liability Current Accounts Payable And Accrued Expenses OperatingLeaseLiabilityCurrentAccountsPayableAndAccruedExpenses	4202000
CY2022Q4	alhc	Operating Lease Liability Non Current Long Term Lease Liabilities OperatingLeaseLiabilityNonCurrentLongTermLeaseLiabilities	3698000
CY2023	alhc	Fixed Operating Lease Costs FixedOperatingLeaseCosts	2817000
CY2022	alhc	Fixed Operating Lease Costs FixedOperatingLeaseCosts	3415000
CY2021	alhc	Fixed Operating Lease Costs FixedOperatingLeaseCosts	3466000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	431000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	352000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	365000
CY2023	us-gaap	Lease Cost LeaseCost	3248000
CY2022	us-gaap	Lease Cost LeaseCost	3767000
CY2021	us-gaap	Lease Cost LeaseCost	3831000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	3510000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	4214000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	3817000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y7M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.12
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M18D
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.075
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	385000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Finance Lease Liability RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability	0
CY2023Q4	alhc	Operating Lease Asset OperatingLeaseAsset	9819000
CY2022Q4	alhc	Operating Lease Asset OperatingLeaseAsset	5548000
CY2023Q4	alhc	Finance Lease Assets FinanceLeaseAssets	140000
CY2022Q4	alhc	Finance Lease Assets FinanceLeaseAssets	277000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9959000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5825000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1597000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4050000
CY2023Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	120000
CY2022Q4	us-gaap	Finance Lease Liability Current FinanceLeaseLiabilityCurrent	152000
CY2023Q4	alhc	Operating Lease Liabilities Non Current OperatingLeaseLiabilitiesNonCurrent	8974000
CY2022Q4	alhc	Operating Lease Liabilities Non Current OperatingLeaseLiabilitiesNonCurrent	3578000
CY2023Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	0
CY2022Q4	us-gaap	Finance Lease Liability Noncurrent FinanceLeaseLiabilityNoncurrent	120000
CY2023Q4	alhc	Lease Liability LeaseLiability	10691000
CY2022Q4	alhc	Lease Liability LeaseLiability	7900000
CY2023Q4	us-gaap	Loss Contingency Accrual Carrying Value Current LossContingencyAccrualCarryingValueCurrent	913000
CY2023Q4	alhc	Amounts Accrued For Legal Proceedings AmountsAccruedForLegalProceedings	0
CY2022Q4	alhc	Amounts Accrued For Legal Proceedings AmountsAccruedForLegalProceedings	0
CY2023	alhc	Legal Fees Paid LegalFeesPaid	518000
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	1000000000
CY2022	alhc	Legal Fees Paid LegalFeesPaid	1326000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	2599000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2485000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2298000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2198000
CY2023Q4	alhc	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	4878000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	14458000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	3887000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	10571000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Next Twelve Months FinanceLeaseLiabilityPaymentsDueNextTwelveMonths	123000
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Two FinanceLeaseLiabilityPaymentsDueYearTwo	0
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Three FinanceLeaseLiabilityPaymentsDueYearThree	0
CY2023Q4	us-gaap	Finance Lease Liability Payments Due Year Four FinanceLeaseLiabilityPaymentsDueYearFour	0
CY2023Q4	alhc	Finance Lease Liability Payments Due After Year Four FinanceLeaseLiabilityPaymentsDueAfterYearFour	0
CY2023Q4	us-gaap	Finance Lease Liability Payments Due FinanceLeaseLiabilityPaymentsDue	123000
CY2023Q4	us-gaap	Finance Lease Liability Undiscounted Excess Amount FinanceLeaseLiabilityUndiscountedExcessAmount	3000
CY2023Q4	us-gaap	Finance Lease Liability FinanceLeaseLiability	120000
CY2023	us-gaap	Sublease Income SubleaseIncome	565000
CY2022	us-gaap	Sublease Income SubleaseIncome	393000
CY2021	us-gaap	Sublease Income SubleaseIncome	229000
CY2023	us-gaap	Impairment Lessor Asset Under Operating Lease ImpairmentLessorAssetUnderOperatingLease	0
CY2022	us-gaap	Impairment Lessor Asset Under Operating Lease ImpairmentLessorAssetUnderOperatingLease	510000
CY2021	us-gaap	Impairment Lessor Asset Under Operating Lease ImpairmentLessorAssetUnderOperatingLease	0
CY2023	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	1
CY2023	us-gaap	Loss Contingency Settlement Agreement Date LossContingencySettlementAgreementDate	August 15, 2023
CY2023Q3	us-gaap	Litigation Settlement Amount Awarded To Other Party LitigationSettlementAmountAwardedToOtherParty	913000

Files In Submission

Name	View Source	Status
0000950170-24-021154-index-headers.html	Edgar Link	pending
0000950170-24-021154-index.html	Edgar Link	pending
0000950170-24-021154.txt	Edgar Link	pending
0000950170-24-021154-xbrl.zip	Edgar Link	pending
alhc-20231231.htm	Edgar Link	pending
alhc-20231231.xsd	Edgar Link	pending
alhc-ex21_1.htm	Edgar Link	pending
alhc-ex23_1.htm	Edgar Link	pending
alhc-ex31_1.htm	Edgar Link	pending
alhc-ex31_2.htm	Edgar Link	pending
alhc-ex32_1.htm	Edgar Link	pending
alhc-ex32_2.htm	Edgar Link	pending
alhc-ex3_2.htm	Edgar Link	pending
alhc-ex97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img21758277_0.jpg	Edgar Link	pending
img21758277_1.jpg	Edgar Link	pending
img21758277_2.jpg	Edgar Link	pending
img21758277_3.jpg	Edgar Link	pending
img21758277_4.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
alhc-20231231_htm.xml	Edgar Link	completed
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALHC
Alignment Healthcare, Inc. Stock $alhc

2024 Q1 Form 10-K Financial Statement

#000095017024021154 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALHC Alignment Healthcare, Inc. Stock $alhc

2024 Q1 Form 10-K Financial Statement

#000095017024021154 Filed on February 27, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALHC
Alignment Healthcare, Inc. Stock $alhc